• About
  • Masthead
  • License Content
  • Advertise
  • Submit Press Release
  • RSS/Email List
  • Write for us
  • Contact us
2 Minute Medicine
No Result
View All Result

No products in the cart.

SUBSCRIBE
  • Specialties
    • Cardiology
    • Chronic Disease
    • Dermatology
    • Emergency
    • Endocrinology
    • Gastroenterology
    • Imaging and Intervention
    • Infectious Disease
    • Nephrology
    • Neurology
    • Obstetrics
    • Oncology
    • Ophthalmology
    • Pediatrics
    • Preclinical
    • Psychiatry
    • Public Health
    • Pulmonology
    • Rheumatology
    • Surgery
  • The Scan
  • Wellness
  • Classics™
    • 2MM+ Online Access
    • Paperback and Ebook
  • Rewinds
  • Visual
  • Partners
    • License Content
    • Submit Press Release
    • Advertise with Us
  • AccountLog-in/out
    • Subscribe
    • Sign-in
    • My account
2 Minute Medicine
  • Specialties
    • Cardiology
    • Chronic Disease
    • Dermatology
    • Emergency
    • Endocrinology
    • Gastroenterology
    • Imaging and Intervention
    • Infectious Disease
    • Nephrology
    • Neurology
    • Obstetrics
    • Oncology
    • Ophthalmology
    • Pediatrics
    • Preclinical
    • Psychiatry
    • Public Health
    • Pulmonology
    • Rheumatology
    • Surgery
  • The Scan
  • Wellness
  • Classics™
    • 2MM+ Online Access
    • Paperback and Ebook
  • Rewinds
  • Visual
  • Partners
    • License Content
    • Submit Press Release
    • Advertise with Us
  • AccountLog-in/out
    • Subscribe
    • Sign-in
    • My account
SUBSCRIBE
2 Minute Medicine
Subscribe
Home The Classics General Medicine Classics

The MELD score: Predicting survival in end-stage liver disease [Classics Series]

byAndrew Cheung, MD MBA
March 24, 2014
in General Medicine Classics, Surgery Classics, The Classics
Reading Time: 2 mins read
0
Share on FacebookShare on Twitter

Image: PD

1. The Model for End-Stage Liver Disease (MELD) is a reliable tool for predicting short-term survival in patients with advanced liver disease

2. The score is generalizable to diverse etiologies and a wide range of disease severity

Original Date of Publication: February 2001

Study Rundown: The Model for End-Stage Liver Disease (MELD) was originally developed to predict outcomes in patients after a transjugular intrahepatic portosystemic shunt (TIPS) procedure. The study reported here assessed whether the model could reliably predict short-term survival in patients with chronic liver disease. The investigators found that MELD scores were a good predictor of 1-week, 3-month and 1-year survival, which had important implications for the model’s use in the allocation of donor livers. Previously, the Child-Turcotte-Pugh (CTP) system was used to rank patients according to urgency and medical need, however the broad classifications made it difficult to rank patients according to severity of disease. Another issue with CTP scores was the subjectivity involved in some of the criteria (e.g., assessment of ascites and encephalopathy). The MELD criteria are an improvement on these aspects of CTP scores as patients are assigned a numerical score based on objective measures.

Please click to read study in Hepatology

In-Depth [cohort study]: This study, originally published in Hepatology in 2001, evaluated the validity of the MELD score for predicting survival in patients with end-stage liver disease. The model uses measures of serum creatinine, total serum bilirubin, International Normalized Ratio (INR) for prothrombin time and etiology of cirrhosis to assess disease severity. The model was assessed in four independent samples, which included patients hospitalized with advanced end-stage liver disease, ambulatory patients with noncholestatic cirrhosis, ambulatory patients with primary biliary cirrhosis (PBC) and a historical group of cirrhotic patients from a period when liver transplantation was not widely available. The primary outcome measure was 3-month survival and validity was also assessed for predicting 1-week and 1-year survival. The c-statistics for 3-month mortality in the hospitalized, ambulatory noncholestatic, ambulatory PBC and historical groups respectively were 0.87, 0.80, 0.87 and 0.78. These values changed minimally when etiology of disease was excluded from the model. The MELD score was found to be a reliable tool to predict survival in patients with chronic liver disease.

RELATED REPORTS

Study reports improvement in pediatric liver transplant outcomes over past decades

The VALENCE trial: Sofosbuvir–ribavirin for hepatitis C [Classics Series]

LI-RADS outlines standards for liver imaging studies assessing HCC [Classics Series]

By Adrienne Cheung, Andrew Cheung, M.D.

© 2013 2minutemedicine.com. All rights reserved. No works may be reproduced without written consent from 2minutemedicine.com. Disclaimer: We present factual information directly from peer reviewed medical journals. No post should be construed as medical advice and is not intended as such by the authors or by 2minutemedicine.com. PLEASE SEE A HEALTHCARE PROVIDER IN YOUR AREA IF YOU SEEK MEDICAL ADVICE OF ANY SORT. Content is produced in accordance with fair use copyrights solely and strictly for the purpose of teaching, news and criticism. No benefit, monetary or otherwise, is realized by any participants or the owner of this domain.

Tags: Child-Turcotte-Pughcirrhosisliver diseaseMELD scoreModel for End-Stage Liver Diseas
Previous Post

Algorithm effective in identifying at-risk infants for becoming overweight

Next Post

Adjusted neonatal care coincides with decreased morbidity and mortality

RelatedReports

Chronic Disease

Study reports improvement in pediatric liver transplant outcomes over past decades

September 19, 2022
The ABCD2 score: Risk of stroke after Transient Ischemic Attack (TIA) [Classics Series]
Infectious Disease Classics

The VALENCE trial: Sofosbuvir–ribavirin for hepatitis C [Classics Series]

August 17, 2022
The ABCD2 score: Risk of stroke after Transient Ischemic Attack (TIA) [Classics Series]
Radiology Classics

LI-RADS outlines standards for liver imaging studies assessing HCC [Classics Series]

August 12, 2022
Maternal cell-free DNA sequencing superior to standard aneuploidy screening [CARE Study]
Chronic Disease

Germline mutations in CIDEB confer protection from liver disease

August 9, 2022
Next Post
Obtaining consent for c-section during labor may be suboptimal

Adjusted neonatal care coincides with decreased morbidity and mortality

Fibrosis linked with mortality in nonischemic dilated cardiomyopathy patients

Longer duration of obesity increases risk of coronary heart disease

Soy supplementation does not reduce risk of prostate cancer recurrence

Androgen deprivation therapy increases risk of kidney injury in prostate cancer patients

License Our Award-Winning Physician-Written Medical News and Visual Abstracts

2 Minute Medicine is the leading authoritative medical news licensing service, and the only with reports written by practicing doctors.

LICENSE CONTENT

2MM+ Premium Access

No ads & unlimited access to all current reports, over 9000 searchable archived reports, visual abstracts, Weekly Rewinds, and the online edition of The Classics Series™ textbook.

Subscription Options
2 Minute Medicine

2 Minute Medicine® is an award winning, physician-run, expert medical media company. Our content is curated, written and edited by practicing health professionals who have clinical and scientific expertise in their field of reporting. Our editorial management team is comprised of highly-trained MD physicians. Join numerous brands, companies, and hospitals who trust our licensed content.

Recent Reports

  • Childhood maltreatment may cause mental health problems
  • #VisualAbstract: Hydrochlorothiazide does not impact risk of kidney-stone recurrence
  • Metformin use may decrease risk of osteoarthritis development
License Content
Terms of Use | Disclaimer
Cookie Policy
Privacy Statement (EU)
Disclaimer

© 2021 2 Minute Medicine, Inc. - Physician-written medical news.

  • Specialties
    • Cardiology
    • Chronic Disease
    • Dermatology
    • Emergency
    • Endocrinology
    • Gastroenterology
    • Imaging and Intervention
    • Infectious Disease
    • Nephrology
    • Neurology
    • Obstetrics
    • Oncology
    • Ophthalmology
    • Pediatrics
    • Preclinical
    • Psychiatry
    • Public Health
    • Pulmonology
    • Rheumatology
    • Surgery
  • The Scan
  • Wellness
  • Classics™
    • 2MM+ Online Access
    • Paperback and Ebook
  • Rewinds
  • Visual
  • Partners
    • License Content
    • Submit Press Release
    • Advertise with Us
  • Account
    • Subscribe
    • Sign-in
    • My account

© 2021 2 Minute Medicine, Inc. - Physician-written medical news.

Want more physician-written
medical news?

Join over 10 million yearly readers and numerous companies. For healthcare professionals
and the public.

Subscribe for free today!

Subscription options